Jim Schwartz, RPh, president of the National Community Oncology Dispensing Association and executive director of pharmacy operations for Texas Oncology, discusses how his practice will handle using CAR T-cell therapies to treat patients.
Jim Schwartz, RPh, president of the National Community Oncology Dispensing Association and executive director of pharmacy operations for Texas Oncology, discusses how his practice will handle using CAR T-cell therapies to treat patients.
Transcript
Are you currently using CAR T therapies at your practice?
CAR T therapy: we are going to be doing CAR T therapy. Baylor Medical Center in Dallas, along with our Texas Oncology physicians, who will be the physicians doing it, are going to do both the Novartis CAR T and [Kite] Pharmaceuticals’ CAR T. So, we’ve had a lot of discussions with them, a lot of meetings. It’ll probably be done in the hospital, inpatient. It’s very expensive, and the people in my practice said, “We’re happy to have Baylor put up the money,” but our doctors will be treating [patients with CAR T therapies].
Are you involved in how to prepare for handling the toxicities of CAR T therapies?
Not intimately, but I’ve got an excellent pharmacist in the bone marrow transplant unit. I went and met with him and he told me more about CAR T than I got on any of the calls. He will be involved in managing—he’s on the outpatient side, but he also helps them on the inpatient side.
So, one of our Texas Oncology pharmacists is going to be involved in that to help monitor the inpatient, because there won’t be a lot of patients, but there will patients that need to be monitored very carefully. That’s why they want to stay in the hospital—it may not happen right away, it may take 2 or 3 days, and he’s part of the group that’s making the care plans. You know, “Once it’s done, here’s what we’re going to watch.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More